Breast cancer is one of the most common cancers among women worldwide. Approximately 20% of breast cancers are HER2-positive, meaning the cancer cells have too many copies of a specific gene called HER2 or human epidermal growth factor receptor 2. HER2-positive breast cancer tends to grow and spread more aggressively than other types. Treatment may involve targeted therapies such as Herceptin, Tykerb and Perjeta that specifically attack HER2 receptors on cancer cells. These drugs inhibit cancer cell growth and division but do not harm normal cells. Having effective targeted therapy options available has changed outcomes for many women with HER2-positive breast cancer.
The global HER2-positive breast cancer treatment market is estimated to be valued at US$ 10.70 Bn in 2024 and is expected to exhibit a CAGR of 2.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the HER2-Positive Breast Cancer market are Jiangsu HengRui Medicine Co., Ltd.,Shanghai Henlius Biotech,Merus N.V.,GeneQuantum,Roche. Roche dominated the market in 2020 due to its blockbuster drug Herceptin. However, biosimilars from Henlius and other emerging players are threatening Roche's market share.
The market offers lucrative opportunities for companies developing new targeted therapies and combination regimens. Ongoing research aims to evaluate newer multi-targeted drugs and immune-oncology combinations to further improve patient outcomes. Several Phase 3 trials evaluating novel agents are expected to read out in the forecast period.
Geographically, North America dominated global revenues in 2020 due to high adoption of premium-priced targeted therapies. However, the Asia Pacific region is expected to exhibit fastest growth over the next decade driven by rising incidence, growing awareness, and increasing accessibility to treatment options across middle-income countries such as India and China. Key market participants are focusing their efforts on expanding access to innovative medicines in emerging Asia Pacific and Latin American markets.
Market drivers
Rising global incidence of breast cancer: According to the World Cancer Research Fund, breast cancer incidence has been rising worldwide at an annual rate of around 0.5% since 2012. An estimated 2.3 million new breast cancer cases and 685,000 breast cancer deaths occured globally in 2020. The increasing disease prevalence is a major factor driving demand for HER2-targeted therapies.
Promising drug pipeline: New drug entrants such as trastuzumab deruxtecan from Daiichi Sankyo offer improved efficacy over existing standard-of-care with a favorable safety profile. Their potential approval and subsequent market entry over the forecast period is expected to significantly boost revenues for HER2-Positive Breast Cancer treatment market.
Market restraints
Entry of biosimilars: The large market size has attracted biosimilar entrants for Roche's blockbuster drug Herceptin, leading to price erosion. Biosimilars capture a bigger share as they are a cost-effective alternative to reference biologics. This poses a restraint on pricing and sales volumes of innovator therapies in the long term.
Intolerability to toxic effects: Existing targeted therapies cause severe side effects such as heart damage, gastro-intestinal disorders like diarrhea in many cases. This limits compliance to treatment regimens thereby impeding maximum real-world benefits of these medications. Tolerance emerges as a major challenge hampering market potential.
Segment Analysis
The global HER2-positive breast cancer market is divided into targeted therapies, immunotherapy, and chemotherapy based on treatment type. Targeted therapies dominate the market currently owing to their efficacy and fewer side effects compared to chemotherapy. Trastuzumab (Herceptin) is the pioneering targeted therapy and is commonly used as adjuvant therapy for a year after surgery for early-stage HER2-positive breast cancer. Trastuzumab is considered the standard treatment for reducing the risk of recurrence after surgery. Pertuzumab (Perjeta) when used in combination with trastuzumab and docetaxel as neoadjuvant (before surgery) or adjuvant (after surgery) treatment reduces the risk of recurrence further when compared to trastuzumab alone.
Global Analysis
Regionally, North America holds the largest share of the global HER2-positive breast cancer market and is expected to remain the dominant regional market over the forecast period owing to the high adoption of advanced treatment options and favorable reimbursement policies in the region. The Asia Pacific market is anticipated to witness the fastest growth during the forecast period supported by rising healthcare expenditure, increasing patient awareness about advanced treatment options, and improving healthcare infrastructure across developing countries. However, high treatment costs associated with targeted therapies remain a barrier, especially in low- and middle-income countries. Key players are focusing on developing affordable biosimilars and expanding access to advanced treatment options in emerging markets to boost sales opportunities.
Get more insights on this topic : https://heyjinni.com/read-blog/170098
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
